Alterity Therapeutics Ltd Stock Price, News & Analysis

Alterity Therapeutics (NASDAQ: ATHE) announced multiple presentations of data from their ATH434-201 Phase 2 clinical trial in Multiple System Atrophy (MSA) at the upcoming 2025 International Congress of Parkinson's Disease and Movement Disorders in Honolulu.

The presentations include an oral platform presentation by CEO David Stamler on how ATH434 slowed disease progression in MSA, and two poster presentations focusing on alpha-synuclein aggregation profiles and clinical/imaging phenotypes. The congress will take place from October 5-9, 2025.

The company aims to educate movement disorder experts about ATH434's potential as a first-ever treatment for MSA.

Alterity Therapeutics (NASDAQ: ATHE) presented promising Phase 2 clinical trial data for ATH434 in Multiple System Atrophy (MSA) at the American Neurological Association Annual Meeting. The study demonstrated that both 50mg and 75mg doses of ATH434 effectively modified disease progression and showed target engagement by reducing iron accumulation in MSA-affected brain regions.

The double-blind trial revealed clinically meaningful efficacy, including reduced disease severity on the MSA activities of daily living scale, improvements in core symptoms, and maintained function in outpatient settings. Importantly, ATH434 was well-tolerated with adverse event rates similar to placebo, and no serious adverse events were attributed to the study drug.

Alterity Therapeutics (NASDAQ: ATHE) has secured binding commitments for a A$20.0 million capital raise through a placement of fully paid ordinary shares to international and Australian professional investors. The placement was conducted at A$0.012 per share, representing a 7.7% discount to the last ASX closing price.

The funding follows positive Phase 2 clinical trial results for ATH434 in Multiple System Atrophy (MSA), which demonstrated clinically meaningful benefits and a favorable safety profile. The proceeds will support non-clinical studies, CMC activities, clinical and regulatory activities for ATH434's development in MSA, and general working capital. The company plans to engage with the FDA to discuss the path forward for ATH434's development.

Alterity Therapeutics (NASDAQ: ATHE), a biotechnology company focused on neurodegenerative disease treatments, announced its CEO David Stamler will present a corporate update at the Biotech Showcase event hosted by Peak Asset Management and Monsoon Communications.

The presentation is scheduled for September 3, 2025, at 12:35 PM AEST (September 2, 2025, at 10:35 PM ET). Interested parties can access the presentation through a Zoom webcast by registering online.

Alterity Therapeutics (NASDAQ: ATHE) reported significant progress in Q4 FY25 for its lead drug candidate ATH434 for Multiple System Atrophy (MSA). The company received FDA Fast Track Designation and reported positive data from two Phase 2 clinical trials. The double-blind study showed 48% reduction in disease severity at 50mg dose and 30% at 75mg dose. The open-label trial demonstrated clinical benefits and slowed brain atrophy.

The company maintains a strong financial position with A$40.66M cash balance as of June 30, 2025, after raising A$26.3M through a placement and receiving an A$3.98M R&D tax incentive refund. Operating cash outflows for the quarter were A$2.35M.

Alterity Therapeutics (NASDAQ: ATHE) announced positive topline data from its ATH434-202 open-label Phase 2 clinical trial for treating Multiple System Atrophy (MSA). The trial demonstrated that ATH434 reduced disease progression by approximately 50% compared to historical controls over 12 months, as measured by the Modified Unified MSA Rating Scale Part I.

Key findings include: 30% of participants reported stable neurological symptoms, stabilization of orthostatic hypotension symptoms, and slowed brain atrophy in MSA-affected areas. The drug showed a favorable safety profile with no serious adverse events related to treatment. Importantly, these results were consistent with the company's previous double-blind Phase 2 trial (ATH434-201), supporting the advancement of ATH434 in MSA treatment.

Alterity Therapeutics (NASDAQ: ATHE) has announced the publication of a groundbreaking study in the Annals of Clinical and Translational Neurology, introducing the MSA Atrophy Index (MSA-AI), a novel MRI-based measurement tool for Multiple System Atrophy (MSA).

The research, developed through Alterity's bioMUSE Natural History Study, employs deep learning methods to track brain atrophy in MSA patients. The study demonstrated that MSA-AI can effectively distinguish MSA from related conditions like Parkinson's disease and Dementia with Lewy Bodies, with significantly lower scores indicating reduced brain volumes in MSA patients (p < 0.001).

Importantly, the study revealed that 12-month brain volume reductions correlated with clinical disease worsening. This innovative tool will be implemented in Alterity's Phase 2 clinical program and future Phase 3 trials for patient selection and disease progression monitoring.

Alterity Therapeutics (NASDAQ: ATHE) has announced that CEO David Stamler will participate in a Fireside Chat hosted by MST Access on June 25, 2025 (Australia) / June 24, 2025 (US). The presentation will focus on providing updates regarding the company's ATH434 development program in Multiple System Atrophy, following the release of positive Phase 2 data in January. The webcast will take place at 9:00 a.m. AEST for Australian participants and 4:00 p.m. PT / 7:00 p.m. ET for US participants. Registration is required for attendance, and a recording will be made available on the company's website.

Alterity Therapeutics (NASDAQ: ATHE) presented significant findings at the 2025 International MSA Congress regarding their ATH434 Phase 2 clinical trial and related MSA research. The ATH434-201 trial demonstrated promising results, with the 50mg dose showing a 48% relative treatment effect (p=0.02) and the 75mg dose showing a 30% effect (p=0.16) in reducing disease severity on the UMSARS I scale. The drug was well-tolerated with no serious adverse events.

Key research presentations included the development of the MSA Atrophy Index (MSAai), a new imaging biomarker for improved MSA diagnosis and monitoring, and findings from the bioMUSE Natural History Study showing increased α-synuclein levels in skin correlating with greater orthostatic symptoms. The study also demonstrated ATH434's ability to stabilize or reduce iron accumulation in affected brain regions and showed trends in reducing brain atrophy at both dose levels.